Market Newsdesk

BRIDGEWATER, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) — Synchronoss Technologies Inc. (NASDAQ: SNCR), a global leader and innovator in cloud, messaging, digital and IoT platforms and products, today announced that it will be presenting at the 23^rd Annual Needham Virtual Growth Conference on Friday, January 15^th at 1:15 pm ET. A live webcast and replay of the the presentation will be available via the Synchronoss Investor Relations site. The Company will also host 1×1 and small group virtual meetings with investors on Thursday, January 14th.

For additional information or to schedule a meeting with Synchronoss management, please contact your Needham representative or MKR Investor Relations, Synchronoss’ investor relations firm, at [email protected].

About Synchronoss Technologies, Inc.

Synchronoss transforms the way companies create new revenue, reduce costs and delight their subscribers with cloud, messaging, digital and IoT products, supporting hundreds of millions of subscribers across the globe. Synchronoss’ secure, scalable and groundbreaking new technologies, trusted partnerships, and talented people change the way TMT customers grow their businesses. For more information, visit us at www.synchronoss.com.

Contact:

Investors:

Todd Kehrli or Joo-Hun Kim
MKR Investor Relations, Inc.
623-745-4046
[email protected]

MONROVIA, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) — via InvestorWire – Sugarmade, Inc. (OTCMKTS:SGMD) (“Sugarmade” or the “Company”) is pleased to issue the following Letter to Shareholders:

Dear Valued Shareholder,

We would like to express our gratitude for your patience and commitment as we continue to steer Sugarmade into what we hope will be a leadership role in the rapidly growing cannabis marketplace as a vertically integrated farm-to-door solution for cannabis consumers.

2020 was a landmark year for Sugarmade as we established, through our capital and operational investment in Budcars, a cannabis delivery service, a distinct and increasingly vertical model for delivering top cannabis-based products to a growing marketplace. We believe this marketplace remains insufficiently supplied and inconsistently accessible for consumers who want more reliable quality and greater convenience.

To that end, we continue to work to expand our reach. We have experienced some delays in opening our new LA hubs, but we continue to work with the city and anticipate that the situation will be resolved in the near term. We also continue to work to widen our delivery reach overall.

In addition, we continue to verticalize our model, creating a full farm-to-door structure that expect to produce high-quality branded cannabis products positioned in a vertical in-house supply chain. We expect that this will provide Sugarmade with optimal margins. We believe that we will also be better able to make use of 280e tax deductions related to production once we have a more vertical structure in place.

With our vertical vision coming together, our advantageous brand development positioning, and an increasingly promising macro context, we are very excited about the year in front of us.

Once again, we would like to express our sincere gratitude to all our stakeholders. Shareholder value is our number one priority, and we very much look forward to keeping you abreast of Company developments as we reach new milestones along the way.

Best Regards,

Jimmy Chan
Chief Executive Officer

About Sugarmade, Inc.

Sugarmade, Inc. (OTCMKTS:SGMD) is involved in two main business areas: (i) the supply of consumable products to the quick-service restaurant sub-sector of the restaurant industry, and as an importer of non-medical personal protection equipment to business and consumers, and (ii) as an investor in the Budcars licensed cannabis delivery service brand and as an equity owner in Budcars’ first operating location in Sacramento, California. During early 2020, the Company gained a 40% stake in the Budcars brand and in the Sacramento delivery operations by acquiring a 40% stake in Indigo Dye Group (“Indigo”). Under the terms of the agreement with Indigo, Sugarmade acquired an option to purchase an additional 30% interest in Budcars, upon which will provide the Company with a controlling interest. As of the date hereof, the option has not yet been exercised and the Company’s stake in Budcars remains at 40%.

For more information, please visit www.Sugarmade.com.

FORWARD-LOOKING STATEMENTS: This release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management’s current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “would,” “could,” “will” and other words of similar meaning in connection with a discussion of future operating or financial performance. Examples of forward-looking statements include, among others, statements relating to future sales, earnings, cash flows, results of operations, uses of cash and other measures of financial performance.

Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company’s actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others. such as, but not limited to economic conditions, changes in the laws or regulations, demand for products and services of the company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements.

Any forward-looking information provided in this release should be considered with these factors in mind. We assume no obligation to update any forward-looking statements contained herein.

Corporate Contact:
Jimmy Chan
+1-(888)-982-1628
[email protected]

Public Relations:
Tiger Marketing & Branding Agency
[email protected]  
www.TigerGMP.com

Corporate Communications:

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

FLORHAM PARK, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune^® T-cell activating technology, today announced that the Compensation Committee of the PDS Board of Directors approved the grant of inducement stock options covering an aggregate of 202,800 shares of PDS Biotech’s common stock to the newly appointed Chief Financial Officer, Seth Van Voorhees in accordance with Nasdaq Listing Rule 5635(c)(4).

The awards were granted under PDS Biotech’s 2019 Inducement Plan, which was adopted on June 17, 2019 and provides for the granting of equity awards to new employees of PDS Biotech. The stock options have an exercise price of $2.28, the closing price of PDS Biotech’s common stock on January 4, 2021. Each stock option vests over a four-year period, with one-quarter of the shares vesting on the first anniversary of the grant date and then monthly over the following 36 months, subject to continued employment with the company through the applicable vesting dates.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast.” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for its lead asset PDS0101; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: [email protected]

Jacob Goldberger
CG Capital
Phone: +1 (404) 736-3841
Email: [email protected]​

Seattle, WA, Jan. 06, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Baristas Coffee Company/Munchie Magic (OTC:BCCI) is expanding into Oregon adding to its fifty locations in Washington State delivering Ben & Jerry’s ice cream, snacks, and hot foods to customers via delivery partners DoorDash, GrubHub, and Uber Eats. www.baristas.tv  www.munchiemagic.com

The newest of the rapidly expanding Munchie Magic virtual restaurants that deliver Ben & Jerry’s ice cream, snacks, and hot foods through its third-party delivery partners services the central and surrounding downtown Portland, OR core. 

Barry Henthorn, CEO, stated: “The success that Munchie Magic has had in WA state is allowing us to expand into other states. Oregon is a natural progression for us as it is close to our other current locations yet gains us a footprint in Oregon. The technology driving our rapidly expanding business has now been refined to allow the opening of locations in numerous states and soon will support multiple countries as well. We are very enthusiastic about our growth geographically as we continue to develop our relationships with our partners.” 

The media buys, integration, technology development, IP, and other cutting edge marketing for the Munchie Magic virtual restaurants are made possible and are being created via digital media/technology frontrunner ReelTime Media (OTC PINK:RLTR) www.reeltime.com. The integration consolidates and analyses data from the delivery partners DoorDash, Uber Eats, and GrubHub along with sales, cost information, and pertinent demographics from Munchie Magic’s Pick up Partners. ReelTime Media’s capabilities are redefining how companies are evaluating and purchasing their TV, radio, print, and other new digital media.

About Ben & Jerry’s: Ben & Jerry’s is an American company that manufactures ice cream, frozen yogurt, and sorbet. It was founded in 1978 in Burlington, Vermont, and sold in 2000 to British-Dutch conglomerate Unilever. Today it operates globally as a fully owned subsidiary of Unilever. Its present-day headquarters is in South Burlington, Vermont, with its main factory in Waterbury, Vermont. 

About Baristas Coffee Company/ Munchie Magic: Baristas is a publicly-traded national Coffee Company that is recognized throughout the US. It is the majority shareholder of Munchie Magic, Inc. which manages the virtual restaurant which delivers Ben & Jerry’s ice cream, Baristas Coffee, and other snack foods via third party delivery partners. Baristas currently produces and sells coffee related products under the Baristas brand. The Baristas White Coffee single-serve cups compatible with the Keurig 2.0 brewing system is the bestselling product in its category. Baristas also markets other coffee-related products. Baristas gained mainstream exposure when it became the subject of “Grounded in Seattle”, the reality show special feature which aired on WE tv. It has been featured nationally including during Shark Tank on CNBC with Front Montgomery, CNN, ESPN, Food Network, Cosmopolitan Magazine, Forbes Magazine, Modern Living with Kathy Ireland, Sports Illustrated, NFL Monday and Thursday Night Football with Megs McLean, at NASCAR Races, The Grammys, NBA TV, and other notable media. 

Barry Henthorn
[email protected]

Washington, DC, Jan. 06, 2021 (GLOBE NEWSWIRE) — WASHINGTON– Howard University President Wayne A. I. Frederick, a practicing surgeon and person living with sickle cell disease, has a message for Black America: When the time comes, please get vaccinated! As an essential health care worker, educator, father and person at high risk, Dr. Frederick decided to lead by example by producing a public service announcement (PSA) on the importance of getting the coronavirus vaccine. He was among the first to get a vaccine shot at Howard University Hospital, and he hopes his message will encourage others to do the same. Watch the PSA here.

“The coronavirus pandemic is having a significant impact on communities of color, and that narrative won’t change until we take the necessary steps to protect ourselves from exposure,” said Dr. Frederick. “The vaccines that are coming to market are safe and have been proven to be more than 90% effective. However, we can’t get to the other side of this pandemic without you. Wear a mask, keep your social distance, wash your hands and, when the time comes, get vaccinated.”

Dr. Frederick has been on the frontlines of the pandemic in a variety of ways, including making the tough decision to close the University in March, spearheading efforts to set up COVID-19 testing sites in urban communities, co-chairing the Mayor Muriel Bowser’s ReOpen DC subcommittee to address equity and vulnerable populations, and actively speaking out to encourage more vaccine trial participation and, now, vaccination participation.

Nationally, African-Americans are almost three times as likely to die of COVID-19 as whites, according to the Centers for Disease Control and Prevention. In Washington, D.C., African-Americans have comprised 75% of the COVID-19-related deaths in Washington, D.C., while making up only 46% of the city’s population. Public health officials and academics are pointing to underlying health conditions for the severity of the virus in vulnerable populations. 

The PSA, produced in partnership with Howard University’s television station, WHUT-TV; Howard University Hospital; and the Office of University Communications, features several essential health care workers sharing their personal reasons for getting the vaccine. As each person steps up to be vaccinated, they express their “why”: for family, to protect fellow co-workers and in honor of those who’ve lost their lives.  

“I understand there is a lot of hesitancy in minority communities across the country when it comes to healthcare, but this is not an American experiment on Black people. The vaccine is a worldwide cure to end a global pandemic and set us on a path back to normalcy,” said Howard University Hospital CEO Anita Jenkins, who is featured in the PSA getting her shot.“We want the public to know that we trust the science, we’re leading by example and taking the vaccine will help us end this pandemic and the tragic loss of life.”

# # #

About Howard University

Founded in 1867, Howard University is a private, research university that is comprised of 13 schools and colleges. Students pursue studies in more than 120 areas leading to undergraduate, graduate and professional degrees. The University operates with a commitment to Excellence in Truth and Service and has produced one Schwarzman Scholar, three Marshall Scholars, four Rhodes Scholars, 11 Truman Scholars, 25 Pickering Fellows and more than 165 Fulbright recipients. Howard also produces more on-campus African-American Ph.D. recipients than any other university in the United States. For more information on Howard University, visit www.howard.edu. 

Attachments

• President Frederick Vaccine
• HUH Vaccine Volunteers

AUSTIN, TX and DURHAM, NC, Jan. 06, 2021 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present at the 39^th Annual J.P. Morgan Healthcare Conference being held virtually January 11-14, 2021.

Presentation Details

Conference: 39th Annual J.P. Morgan Healthcare Conference
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: January 14, 2021
Time: 5:20 p.m. EST
Webcast Link: Available Here

The live webcast of the presentation will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 30 days following the presentation date.

About Shattuck Labs, Inc.

Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC^®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor Contact:

Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
[email protected]

Media Contact:

Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
[email protected]